Search
Beractant
go.drugbank.com/drugs/DB06761ApprovedIn comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality. … In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnUnfortunately, many patients experience a relapse or develop resistance to these drugs. … Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.
Votucalis
go.drugbank.com/drugs/DB05032InvestigationalrEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Iobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
Amorolfine
go.drugbank.com/drugs/DB09056ApprovedWithdrawnIt is available in the form of a 5% amorolfine nail lacquer used to treat onychomycosis (fungal infection of the toe- and fingernails). … This inhibition affects fungal sterol synthesis pathways, depleting ergosterol and causing ignosterol to accumulate in the fungal cytoplasmic cell membranes.
Products: AMOROLFINE NAIL LACQUER 5%W/V, Mycofine 5% w/v Nail LacquerAmaranthus retroflexus pollen
go.drugbank.com/drugs/DB10381ApprovedAmaranthus retroflexus pollen is the pollen of the Amaranthus retroflexus plant. Amaranthus retroflexus pollen is mainly used in allergenic testing.
Mixtures: Number Two Weed MixtureAminolevulinic acid
go.drugbank.com/drugs/DB00855ApprovedInvestigationalA compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]